185 related articles for article (PubMed ID: 35459391)
1. Bone disesase in end-stage kidney disease - renal and non-renal components.
Sulková SD; Pokorná A; Šafránek R; Pavlíková L; Palička V
Vnitr Lek; 2021; 67(5):258-263. PubMed ID: 35459391
[TBL] [Abstract][Full Text] [Related]
2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
3. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Salam SN; Khwaja A; Wilkie ME
Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
[TBL] [Abstract][Full Text] [Related]
5. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
6. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
7. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities.
Rodzoń-Norwicz M; Norwicz S; Sowa-Kućma M; Gala-Błądzińska A
Endokrynol Pol; 2023; 74(5):490-498. PubMed ID: 37902013
[TBL] [Abstract][Full Text] [Related]
8. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
Nguyen TV; Filson J
Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
Pazianas M; Miller PD
Am J Kidney Dis; 2021 Oct; 78(4):582-589. PubMed ID: 33774081
[TBL] [Abstract][Full Text] [Related]
11. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease: mineral and bone disorder in children.
Wesseling-Perry K; Salusky IB
Semin Nephrol; 2013 Mar; 33(2):169-79. PubMed ID: 23465503
[TBL] [Abstract][Full Text] [Related]
13. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
Komaba H
Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
[TBL] [Abstract][Full Text] [Related]
14. Mineral and bone disorder in chronic kidney disease: pioneering studies.
Floege J; Drüeke TB
Kidney Int; 2020 Oct; 98(4):807-811. PubMed ID: 32998807
[No Abstract] [Full Text] [Related]
15. Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.
Yamada S; Tsuruya K; Kitazono T; Nakano T
Clin Exp Nephrol; 2022 Jul; 26(7):613-629. PubMed ID: 35353283
[TBL] [Abstract][Full Text] [Related]
16. Bone Disease in Chronic Kidney Disease and Kidney Transplant.
Bellorin-Font E; Rojas E; Martin KJ
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615824
[TBL] [Abstract][Full Text] [Related]
17. Effects of Plant-Based Protein Consumption on Kidney Function and Mineral Bone Disorder Outcomes in Adults With Stage 3-5 Chronic Kidney Disease: A Systematic Review.
Burstad KM; Cladis DP; Wiese GN; Butler M; Hill Gallant KM
J Ren Nutr; 2023 Nov; 33(6):717-730. PubMed ID: 37116624
[TBL] [Abstract][Full Text] [Related]
18. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
[TBL] [Abstract][Full Text] [Related]
20. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
